SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of expected Phase 3 APPROACH topline results for HLP003, its adjunctive major-depression treatment; traders view the readout as a high-stakes catalyst and debate whether the results will validate the programs promise. Optimism about the drugs potential is countered by concerns about clinical risk, dilution, and managements record.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxiss Investor Day and approaching FDA decisions for ulixacaltamide in essential tremor and relutrigine in developmental and epileptic encephalopathies are driving attention, alongside discussion of broader relutrigine trial data and launch preparations. Traders largely praise the commercial plans and potential markets, while some caution that approval, review timing and uptake remain uncertain.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application, citing insufficient evidence of benefit without a statistically significant overall-survival result despite strong progression-free-survival data. Traders are reacting to the setback and debating whether future HARMONi-3 results and the broader pipeline can sustain the long-term case.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Strong preliminary REGAIN results in recurrent glioblastoma are driving attention, with traders highlighting high response rates in a small evaluable group and survival among treated patients. The community is broadly bullish but notes that durability, safety, and results as enrollment expands still need validation, with managements review of the data a focal point.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic stake is drawing attention as traders treat the company as a potential proxy for Anthropic ahead of its reported IPO filing, though some question how much value the holding adds and whether it can offset modest growth in Zooms core business. A recent earnings beat, raised full-year outlook and larger buyback also drew bullish reactions, while the softer near-term outlook tempered enthusiasm.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

A nationwide FAA ground stop triggered by an air-traffic-control communications outage is driving attention, with widespread delays and cancellations raising concerns about Deltas operational costs and near-term results. Traders are split between viewing the disruption as a temporary setback now that the stop has been lifted and fearing lingering travel impacts; speculation about cyberattacks or deliberate action is unverified.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound are driving discussion, with traders debating whether liquidation-driven selling and concerns about ETF flows, the Binance hack and macro headwinds point to further downside or an oversold bounce. Bears warn of new lows, while bulls see support holding and argue the pullback may be nearing a bottom.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Squibbs quarterly results beat expectations and lifted its revenue outlook, while its adjusted earnings outlook was lowered because of licensing-related charges. Traders welcomed the sales performance but debated whether pipeline progress can offset patent-expiration pressures, with some also noting weak price momentum.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

VXX is drawing attention as traders react to a volatility uptick amid risk-off concerns and debate whether it signals a broader market pullback or a short-lived spike. Some are buying it as portfolio protection, while others expect volatility to fade and point to the products futures-roll decay.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroups quarterly results beat expectations, but the shares sold off, prompting debate over why strong results arent lifting the stock. Traders point to pressure in the card business and higher loan-loss provisions, while some view the weakness as a buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$QQQ $CRWV 📊 **CRWV: Key Support &amp; Resistance Levels to Watch** 
 
CoreWeave is facing renewed selling pressure after Friday&#39;s decline. However, I&#39;m watching several important technical levels that could determine its next move. 
 
🟢 **Support Levels:** 
- $49–$50: Key near-term support 
- $45–$46: Secondary support 
 
🔴 **Resistance Levels:** 
- $56–$57: First breakout level 
- $59–$61: Next resistance zone 
 
📉 **Technical Outlook:** 
 
RSI is around 43, while MACD remains below zero. Momentum is still weak, but the stock is approaching an important support area. 
 
🚀 **What I&#39;m Watching:** 
 
1. Can CRWV hold above $49–$50? 
2. Will buyers step in with stronger volume? 
3. Can the stock reclaim $56.58?

StockTwits Web

CoreWeave Inc

 📊 **CRWV: Key Support & Resistance Levels to Watch** 
 
CoreWeave is facing renewed selling pressure after Friday's decline. However, I'm watching several important technical levels that could determine its next move. 
 
🟢 **Support Levels:** 
- $49–$50: Key near-term support 
- $45–$46: Secondary support 
 
🔴 **Resistance Levels:** 
- $56–$57: First breakout level 
- $59–$61: Next resistance zone 
 
📉 **Technical Outlook:** 
 
RSI is around 43, while MACD remains below zero. Momentum is still weak, but the stock is approaching an important support area. 
 
🚀 **What I'm Watching:** 
 
1. Can CRWV hold above $49–$50? 
2. Will buyers step in with stronger volume? 
3. Can the stock reclaim $56.58?